WebCompany profile page for Bird Rock Bio Inc including stock price, company news, press releases, executives, board members, and contact information
Did you know?
WebMr. Saad is currently a Partner and Chief Operating Officer of Alethea Capital Management, LLC, an asset management firm based in San Diego. Between August 2014 and February 2024 he served as the Chief Financial Officer of Bird Rock Bio, Inc., a clinical stage biopharmaceutical company focused on developing innovative immuno-inflammatory … WebFeb 8, 2024 · LA JOLLA, Calif.—In late 2016, Bird Rock Bio Inc., a clinical-stage biopharmaceutical company, reported that it had received approval to start a two-part Phase 1 clinical trial for namacizumab, a therapeutic antibody to the cannabinoid 1 (CB1) receptor.The company has also entered into an agreement with GE Healthcare for …
WebMar 16, 2016 · LA JOLLA, Calif., March 16, 2016 /PRNewswire/ -- Bird Rock Bio, Inc., a clinical stage biopharmaceutical company, today announced positive results from two clinical studies assessing the safety and pharmacokinetics of gerilimzumab, a novel anti-IL-6 cytokine antibody for the treatment of inflammatory diseases, including rheumatoid … WebFind company research, competitor information, contact details & financial data for Bird Rock Bio, Inc. of San Diego, CA. Get the latest business insights from Dun & …
WebContact Info. bird rock bio, inc. 505 COAST BLVD SOUTH. LA JOLLA CA 92037. Business Phone: 858-587-4815. http://www.birdrockbio.com/2024/09/13/bird-rock-bio-completes-clinical-trial-of-nimacimab-in-patients-with-fatty-liver-disease/
WebMay 28, 2024 · Bird Rock Bio, Inc., a clinical stage biopharmaceutical company, announced today that the Company has filed an investigational new drug (IND) …
WebMay 28, 2024 · Bird Rock Bio owns the worldwide rights to nimacimab, with patents issued in the U.S. and other territories, including claims to cannabinoid 1 receptor antibodies … filósofo voltaireWebBird Rock Bio is focused on the discovery and development of novel biologic therapeutics that meet the medical and commercial needs for China’s patients and healthcare system and that have the potential to be disruptive globally. RYI-008 is a novel, extremely potent monoclonal antibody that is highly selective to IL-6, a cytokine widely ... filósofo spinoza benedictusWebMay 28, 2024 · Bird Rock Bio, Inc., a clinical stage biopharmaceutical company, announced today that the Company has filed an investigational new drug (IND) application with the U.S. Food and Drug Administration (FDA) for the initiation of a phase 2 clinical study of nimacimab, also known as RYI-018, in patients with one of the following renal dis filosophy amazonWebCompany profile page for Bird Rock Bio Inc including stock price, company news, press releases, executives, board members, and contact information filósofo zizekWebOct 24, 2024 · Akero Therapeutics Inc., Cambridge, Mass. Jennie Walters GS-0976, ndi-010976 Amgen Inc. Atlas Venture Jecure Therapeutics Inc. Versant Partners Inc. Bird Rock Bio Inc. Nimbus... Read More BioCentury Jun 25, 2024 filosofo zizekWebOct 17, 2024 · LA JOLLA, Calif., Oct. 17, 2024 /PRNewswire/ -- Bird Rock Bio, Inc., a clinical stage biopharmaceutical company, announced today the successful completion of their phase 1b study of nimacimab, also known as RYI-018, and the planned submission of an investigational new drug (IND) application to the U.S. Food and Drug Administration … filosofos aztecasWebOct 24, 2024 · Bird Rock Bio Inc., La Jolla, Calif. Johnson & Johnson (NYSE:JNJ), New Brunswick, N.J. Business: Hepatic, Renal Chris Lieu namacizumab Bird Rock Bio Inc. … filosz